Piper Sandler Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $53

Moomoo NewsDec 2 07:32 ET · Ratings

Dyne Therapeutics Initiated at Outperform by RBC Capital

Dow JonesNov 26 05:12 ET · Ratings

Dyne Therapeutics Analyst Ratings

BenzingaNov 26 05:00 ET · Ratings

RBC Capital Initiates Dyne Therapeutics(DYN.US) With Buy Rating, Announces Target Price $45

Moomoo NewsNov 25 20:31 ET · Ratings

Form 144 | Dyne Therapeutics(DYN.US) Insider Proposes to Sell 49.25 Million in Common Stocks

SEC FILLINGS DISCLOSED/ Nov 14, $Dyne Therapeutics(DYN.US)$ Insider ForDyne B.V. intends to sell 1.5 million shares of its common stock on Nov 14, with a total market value of approximately $49.25

Moomoo NewsNov 14 17:02 ET

Dyne Therapeutics Reveals Q3 Results and Trial Updates

TipRanksNov 13 22:58 ET